A Phase I/II First in Human, Open Label, Multi-centre, Dose Escalation, Dose Finding, Safety and Tolerability Study of BVX20 administered intravenously in patients with Relapsed/Refractory CD20+ B cell Non Hodgkin's Lymphoma

Trial Profile

A Phase I/II First in Human, Open Label, Multi-centre, Dose Escalation, Dose Finding, Safety and Tolerability Study of BVX20 administered intravenously in patients with Relapsed/Refractory CD20+ B cell Non Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs BVX 20 (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Mar 2013 Planned end date 15 Jun 2014 added as reported by Clinical Trials Registry - India record.
    • 04 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top